ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The integrative analysis based on super-enhancer related genes for predicting different subtypes and prognosis of patient with lower-grade glioma

Hu, Yungang; Yang, Qingqing; Cai, Shuzhou; Wang, Wei; Fu, Shiyin*wuhan univ sci & technol; jinchu univ technol
Frontiers in Genetics2023-4-7DOI: 10.3389/fgene.2023.1085584
7阅读
引用收藏
分享

摘要

Objective: Emerging evidence revealed that super-enhancer plays a crucial role in the transcriptional reprogramming for many cancers. The purpose aimed to explored how the super-enhancer related genes affects the prognosis and tumor immune microenvironment (TIME) of patients with low-grade glioma (LGG).Methods: In this study, the differentially expressed genes (DEGs) between LGG cohorts and normal brain tissue cohort were identified by the comprehensive analysis of the super-enhancer (SE) related genes. Then non-negative matrix factorization was performed to seek the optimal classification based on the DEGs, while investigating prognostic and clinical differences between different subtypes. Subsequently, a prognostic related signature (SERS) was constructed for the comprehensive evaluation in term of individualized prognosis, clinical characteristics, cancer markers, genomic alterations, and immune microenvironment of patients with LGG.Results: Based on the expression profiles of 170 DEGs, we identified three SE subtypes, and the three subtypes showed significant differences in prognostic, clinicopathological features. Then, nine optimal SE-related genes were selected to construct the SERS through the least absolute shrinkage and selection operator Cox regression analysis. Survival analysis showed that SERS had strong and stable predictive ability for the prognosis of LGG patients in the The Cancer Genome Atlas, China Glioma Genome Atlas, and Remdrandt cohorts, respectively. We also found that SERS was highly correlated with clinicopathological features, tumor immune microenvironment, cancer hallmarks, and genomic alterations in LGG patients. In addition, the predictive power of SERS for immune checkpoint inhibitor treatment is also superior. The qRT-PCR results and immunohistochemical results also confirmed the difference in the expression of four key genes in normal cells and tumors, as well as in normal tissues and tumor tissues.Conclusion: The SERS could be suitable to utilize individualized prognosis prediction and immunotherapy options for LGG patients in clinical application.

学科与关键词

关键词
super-enhancerlower-grade gliomaprognostic signaturetumor immune microenvironmentimmunotherapy
相关
加载中…
  • Development and Validation of a Novel Prognostic Model for Lower-Grade Glioma Based on Enhancer RNA-Regulated Prognostic Genes
    Tian, Wei; Yan, Guangcan; Chen, Kegong; Han, Xinhao; Zhang, Wei; Sun, Lin; Zhang, Qi; Zhang, Yafeng; Li, Yan; Liu, Meina*; Zhang, Qiuju*Frontiers in Oncology, 2022, 12: 714338.被引 4
  • A Novel Prognostic Tool for Glioma Based on Enhancer RNA-Regulated Immune Genes
    Tian, Wei; Chen, Kegong; Yan, Guangcan; Han, Xinhao; Liu, Yanlong; Zhang, Qiuju*; Liu, Meina*Frontiers in Cell and Developmental Biology, 2022, 9: 798445.被引 7
  • Dissecting super-enhancer heterogeneity: time to re-examine cancer subtypes?
    Wu, Tan; Huang, Hao; Wang, Xin*Trends in Genetics, 2022, 38(12): 1199-1203.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Genetics
发表日期
2023-04-07
卷期
第 14 卷
页码
1085584
DOI
10.3389/fgene.2023.1085584
成果收录
SCIE

作者

  • H

    Hu, Yungang (第一作者)

    wuhan univ sci & technol

  • Y

    Yang, Qingqing

    wuhan univ sci & technol

查看全部 5 位作者收起作者
  • C

    Cai, Shuzhou

    wuhan univ sci & technol

  • W

    Wang, Wei

    wuhan univ sci & technol

  • F

    Fu, Shiyin (通讯)

    jinchu univ technol

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417